SALIX PHARMACEUTICALS, INC.: Salix Provides Update on FDA Submission for PLENVU®

Salix Pharmaceuticals, Ltd., one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. have received notice that the U.S. Food and Drug Administration has extended the PDUFA action date for its review of the New Drug Application for PLENVU®* (NER1006) by three months to May 13, 2018. Read More »